A Phase 2 interventional study of Enzalutamide and exemestane in Breast Cancer, sponsored by Pfizer. Completed at 135 sites in 7 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-02.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing enzalutamide in Breast Neoplasms — 1 open to participants now, 3 under way, none of them phase 3. enzalutamide · Breast Neoplasms.
Among the 13 studies testing enzalutamide in Breast Neoplasms, this one has the largest enrollment, is one of 2 that started in 2013, is one of 9 in phase 2, and was the 3rd registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →1 of the 13 studies testing enzalutamide in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 247 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 61 across the 13 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 13 have an industry lead sponsor. The 7 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
182 studies in Breast Neoplasms by Pfizer: 6 open now, 26 under way, 7 of them phase 3. Of 145 finished, 94 (65%) have results posted.
Among the 182 studies in Breast Neoplasms by Pfizer, this one is the 29th largest by enrollment of the 121 interventional ones that give a count, is one of 10 that started in 2013, is one of 43 in phase 2, and was the 77th registered.
Pfizer’s Breast Neoplasms studies by the year they started, since 1998.
2 of the studies testing enzalutamide in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02750358Memorial Sloan Kettering Cancer CenterFeasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer | 2027-05 |
| NCT06099769Memorial Sloan Kettering Cancer CenterA Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies testing enzalutamide in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 182 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if enzalutamide given in combination with exemestane is safe and effective in patients with advanced breast cancer.
This is a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estrogen or Progesterone Receptor Positive and HER2-Normal.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Enzalutamide 160 mg/day administered as four 40mg soft gelatin capsules by mouth once daily with or without food and exemestane 50mg (two 25mg tablets overencapsulated as a single capsule during the blinded portion of the study and two 25mg tablets after unblinding) once daily after food.
Drug: Enzalutamide · Drug: exemestane
Placebo and exemestane 25mg (overencapsulated to match 50mg dose during the blinded portion of the study and one 25mg tablet without placebo after unblinding) once daily after food.
Drug: exemestane · Drug: Placebo (for enzalutamide)
160 mg/day administered as four 40mg soft gelatin capsules by mouth once daily with or without food.
Also known as: MDV3100, XTANDI
25mg (overencapsulated to match 50mg dose during the blinded portion of the study and one 25mg tablet after unblinding) by mouth once daily after food.
Also known as: Aromasin
Sugar pill manufactured to mimic enzalutamide administered as four soft gelatin capsules by mouth once daily with or without food.
50mg (two 25mg tablets overencapsulated as a single capsule during the blinded portion of the study and two 25mg tablets after unblinding) by mouth once daily after food.
Also known as: Aromasin
Progression Free Survival (PFS): Intent-to-Treat (ITT) Population By Interactive Web Recognition System (IWRS)
PFS was defined as the time in months from randomization to the first documentation of progression of disease (PD) or death on study due to any cause, whichever occurred first. PD according to response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) was defined as greater than or equal to (\>=) 20 percent (%) increase in the sum of diameters of the target lesions taking as a reference the smallest sum recorded since the start of treatment or unequivocal progression in non-target lesions or the appearance of 1 or more new lesions. The analysis of PFS was based on investigator assessment of disease progression. Participants who were not known to have had a PFS event at the analysis date were censored at last tumor assessment date prior to data cutoff or date of new treatment initiation, whichever occurred first.
Time frame: From randomization until PD, last tumor assessment without PD before new antitumor treatment initiation or death due to any cause, whichever occurred first (up to 3 years)
Progression Free Survival (PFS): Diagnostic Positive (DX+) Population By Interactive Web Recognition System (IWRS)
PFS was defined as the time in months from randomization to the first documentation of PD or death on study due to any cause, whichever occurred first. PD according to RECIST 1.1, was defined as \>= 20% increase in the sum of diameters of the target lesions taking as a reference the smallest sum recorded since the start of treatment or unequivocal progression in non-target lesions or the appearance of 1 or more new lesions. The analysis of PFS was based on investigator assessment of disease progression. Participants who were not known to have had a PFS event at the analysis date were censored at last tumor assessment date prior to data cutoff or date of new treatment initiation, whichever occurred first.
Time frame: From randomization until PD, last tumor assessment without PD before new antitumor treatment initiation or death due to any cause, whichever occurred first (up to 3 years)
Clinical Benefit Rate-24 (CBR-24)
CBR-24: Percentage of participants with a best response of complete response (CR), partial response (PR), or stable disease (SD) sustained for atleast 24 weeks, as determined by investigator using RECIST 1.1. CR: Disappearance of all (target and non-target) lesions and normalization of tumor marker level for non-target lesions. All lymph nodes (target and non-target) must be non-pathological in size (less than \[\<\] 10 millimeter \[mm\] short axis). PR: \>=30% decrease in sum of diameters of target lesions, using baseline sum diameters as reference. SD: Neither sufficient reduction to qualify as PR nor sufficient increase to qualify as PD, using the smallest sum diameters during study as reference. PD: \>=20% increase (an absolute increase of \>=5 mm) in sum of diameters of target lesions, using the smallest sum during the study as a reference (including baseline sum), or unequivocal progression of existing non-target lesions, or appearance of atleast 1 new target or non-target lesions.
Time frame: From randomization up to 3 years
Best Objective Response Rate
Best objective response rate: Percentage of participants with measurable disease and with a best response of CR or PR according to RECIST 1.1. CR: Disappearance of all (target and non-target) lesions and normalization of tumor marker level for non-target lesions. All lymph nodes (target and non-target) must be non-pathological in size (\<10 mm short axis). PR: Atleast 30% decrease in sum of diameters of target lesions, using baseline sum diameters as reference. Response evaluation was based on investigators' judgment.
Time frame: From randomization until CR or PR, whichever occurred first (up to 3 years)
Duration of Objective Response
Duration of objective response: Time from first documentation of CR or PR, to the first documentation of PD or death due to any cause, whichever occurred first as determined by investigator using RECIST 1.1. CR: Disappearance of all (target and non-target) lesions and normalization of tumor marker level for non-target lesions. All lymph nodes (target and non-target) must be non-pathological in size (\<10 mm short axis). PR: \>=30% decrease in sum of diameters of target lesions, using baseline sum diameters as reference. PD: \>=20% increase (an absolute increase of \>=5 mm) in sum of diameters of target lesions, using the smallest sum during the study as a reference (including baseline sum), or unequivocal progression of existing non-target lesions, or appearance of atleast 1 new target or non-target lesions. Participants with no PD or death (after initial CR or PR) at the analysis date were censored at last tumor assessment date prior to date of new antitumor treatment or data cutoff.
Time frame: From first documentation of CR or PR until PD, or last tumor assessment without PD before new antitumor treatment initiation or death due to any cause, whichever occurred first (up to 3 years)
Time to Response
Time to response: Time from randomization to first documentation of CR or PR. CR: Disappearance of all (target and non-target) lesions and normalization of tumor marker level for non-target lesions. All lymph nodes (target and non-target) must be non-pathological in size (\<10 mm short axis). PR: \>=30% decrease in sum of diameters of target lesions, using baseline sum diameters as reference. PD: \>=20% increase (an absolute increase of \>=5 mm) in sum of diameters of target lesions, using the smallest sum during the study as a reference (including baseline sum), or unequivocal progression of existing non-target lesions, or appearance of atleast 1 new target or non-target lesions. Participants who were not known to have had a CR or PR were censored at last tumor assessment date prior to data cutoff or date of new treatment initiation, whichever occurred first.
Time frame: From randomization until first documentation of CR or PR, or last tumor assessment without PD or death prior to new antitumor treatment initiation, whichever occurred first (up to 3 years)
Time to Progression
Time to progression was defined as the time from the date of randomization to PD defined by the investigator using RECIST 1.1. PD: \>=20% increase (an absolute increase of \>=5 mm) in sum of diameters of target lesions, using the smallest sum during the study as a reference (including baseline sum), or unequivocal progression of existing non-target lesions, or appearance of atleast 1 new target or non-target lesions. Participants who did not experience disease progression, time to progression was right censored at the date of the last tumor assessment prior to data cutoff or date of new antitumor treatment, whichever occurred first.
Time frame: From randomization until PD or last tumor assessment without PD before new antitumor treatment initiation, whichever occurred first (up to 3 years)
Progression Free Survival (PFS) at 6 Months
PFS at 6 months was defined as the percentage of participants with no event of disease progression at Month 6 landmark, estimated by Kaplan-Meier methods. PFS was defined as the time in months from randomization to the first documentation of PD or death on study due to any cause, whichever occurred first. PD: \>=20% increase (an absolute increase of \>=5 mm) in sum of diameters of target lesions, using the smallest sum during the study as a reference (including baseline sum), or unequivocal progression of existing non-target lesions, or appearance of atleast 1 new target or non-target lesions. The analysis of PFS was based on investigator assessment of disease progression.
Time frame: Month 6
Concentration Versus Time Summary of Enzalutamide
Concentration versus time summary was calculated by setting concentration values below limit of quantitation to zero.
Time frame: Predose on Day 29, 57 and 113
Concentration Versus Time Summary of Exemestane
Concentration versus time summary was calculated by setting concentration values below limit of quantitation to zero.
Time frame: Predose, 1 and 6 hour postdose on Day 29, 57, 113 and 169
Concentration Versus Time Summary of N-desmethyl Enzalutamide
N-desmethyl enzalutamide was the active metabolite of enzalutamide. Concentration versus time summary was calculated by setting concentration values below limit of quantitation to zero.
Time frame: Predose on Day 29, 57 and 113
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Core Questionnaire (QLQ-C30) at Weeks 5, 9, 17, 25, 33, 41, 49, 61, 73, 85, 97, 109, 121 and 133: Global Health/Quality of Life
The EORTC QLQ-C30 questionnaire was a standardized instrument developed to assess the quality of life of people with cancer. Participants self-rated their self-care, activity level, pain/discomfort, and mental health during the past week by choosing 1 of 4 possible responses that recorded the level of intensity (not at all, a little, quite a bit, and very much) within each dimension, where higher score=more level of intensity. The questionnaire also asked the participants to rate their overall health or quality of life within the past week on a scale of 1 to 7, where 1 is "very poor" and 7 is "excellent". Higher global health or quality of life scores indicated better overall health or quality of life. In this outcome measure, global health/quality of life scores are presented.
Time frame: Baseline; Weeks 5, 9, 17, 25, 33, 41, 49, 61, 73, 85, 97, 109, 121 and 133
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Module (QLQ-BR23) at Weeks 5, 9, 17, 25, 33, 41, 49, 61, 73, 85, 97, 109, 121 and 133
EORTC QLQ-BR23 was disease-specific module for breast cancer developed as supplement for EORTC QLQ-C30 that assessed quality of life of participants with breast cancer.Participants self-rated on frequent symptoms or problems reported by participants with breast cancer,e.g., pain/discomfort, body satisfaction, and self-esteem during past week by choosing 1 of 4 possible responses that recorded level of intensity (not at all, a little, quite a bit, and very much) within each dimension.Raw scores were then transformed to 0-100 scale for analysis and interpretation, where higher scores=more level of intensity, as per EORTC guidelines.Participants also self-rated on sexual health/interest during last 4 weeks using same scale. In this outcome measure body image functioning, sexual functioning, systemic therapy side effects, upset by hair loss parameters were assessed by EORTC QLQ-BR23 questionnaire,total score for each parameter ranged from 0-100,where higher scores=more level of intensity.
Time frame: Baseline; Weeks 5, 9, 17, 25, 33, 41, 49, 61, 73, 85, 97, 109, 121 and 133
Number of Participants With Positive Androgen Receptor (AR) Expression by Immunohistochemistry (IHC)
Time frame: Day 1, 29, 57, 113 and 169
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious AEs.
Time frame: Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (approximately up to 10.13 years)
Number of Participants With Treatment-Emergent Adverse Events of Grade 3 or Higher Severity
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severity of the AEs was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Only the participants with treatment-emergent AEs of grade 3 (severe) or higher grade were reported in this outcome measure.
Time frame: Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (approximately up to 10.13 years)
Number of Participants With Clinically Significant Vital Sign Abnormalities
Criteria for clinically significant vital sign abnormalities: Systolic blood pressure (SBP): absolute SBP \<90 millimeters of mercury (mmHg) and decrease from baseline (DFB) \>30 mmHg, absolute SBP\>180 mmHg and increase from baseline (IFB) \>40 mmHg, final visit or 2 consecutive visits SBP \>=20 mmHg change from baseline (CFB), most extreme post-baseline SBP \>=140 mmHg, most extreme post-baseline SBP \>=180 mmHg, most extreme SBP \>=140 mmHg and \>=20 mmHg CFB, most extreme SBP \>=180 mmHg and \>=20 mmHg CFB; diastolic blood pressure (DBP): absolute DBP \> 105 mmHg and IFB \>30 mmHg, absolute DBP \<50 mmHg and DFB \>20 mmHg, final visit or 2 consecutive visits DBP \>=15 mmHg CFB, most extreme post-baseline DBP \>=90 mmHg, most extreme post-baseline DBP \>=105 mmHg, most extreme DBP \>=90 mmHg and \>=15 mmHg CFB, most extreme DBP \>=105 mmHg and \>=15 mmHg CFB; heart rate \<50 beats per minute (BPM) and DFB \>20 BPM or heart rate \>120 BPM and IFB \>30 BPM.
Time frame: Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (approximately up to 10.13 years)
Number of Participants With Clinically Significant Laboratory Abnormalities
Laboratory tests included hematology (hematocrit, hemoglobin, platelet count, red blood cell count, total neutrophils \[absolute\] and white blood cell count with differential) and serum chemistry (albumin, alkaline phosphatase, alanine aminotransferase \[ALT\], aspartate transaminase \[AST\], blood urea nitrogen and creatinine, calcium, sodium, potassium, chloride, glucose (non-fasting), lactate dehydrogenase, magnesium, phosphorus/phosphate, total bilirubin, total bicarbonate, total protein and uric acid). Clinically significant abnormality evaluation was based on clinical investigator's judgment.
Time frame: Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (up to 3 years)
Progression Free Survival (PFS): By Electronic Data Capture (EDC)
PFS was defined as the time in months from randomization to the first documentation of PD or death on study due to any cause, whichever occurred first. PD according to RECIST 1.1 was defined \>=20 % increase in the sum of diameters of the target lesions taking as a reference the smallest sum recorded since the start of treatment or unequivocal progression in non-target lesions or the appearance of 1 or more new lesions. The analysis of PFS was based on investigator assessment of disease progression. Participants who were not known to have had a PFS event at the analysis date were censored at last tumor assessment date prior to data cutoff or date of new treatment initiation, whichever occurred first. Cht 1: Enz + Exe = Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg; Cht 2: Enz + Exe= Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg
Time frame: From randomization until PD, last tumor assessment without PD before new antitumor treatment initiation or death due to any cause, whichever occurred first (up to 3 years)
Progression Free Survival (PFS): Diagnostic Positive (DX+) Population By Electronic Data Capture (EDC)
PFS was defined as the time in months from randomization to the first documentation of PD or death on study due to any cause, whichever occurred first. PD according to RECIST 1.1, was defined as \>= 20% increase in the sum of diameters of the target lesions taking as a reference the smallest sum recorded since the start of treatment or unequivocal progression in non-target lesions or the appearance of 1 or more new lesions. The analysis of PFS was based on investigator assessment of disease progression. Participants who were not known to have had a PFS event at the analysis date were censored at last tumor assessment date prior to data cutoff or date of new treatment initiation, whichever occurred first.
Time frame: From randomization until PD, last tumor assessment without PD before new antitumor treatment initiation or death due to any cause, whichever occurred first (up to 3 years)
A total of 247 participants were enrolled.
| Milestone | Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 1: Placebo + Exemestane 25 mg | Cohort 2: Placebo + Exemestane 25 mg |
|---|---|---|---|---|
| Started | 63 | 60 | 64 | 60 |
| Treated | 62 | 60 | 63 | 60 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 63 | 60 | 64 | 60 |
| Withdrew: Adverse event | 4 | 6 | 2 | 2 |
| Withdrew: Death | 1 | 0 | 0 | 0 |
| Withdrew: Disease progression | 51 | 50 | 57 | 52 |
| Withdrew: Withdrawal by subject | 3 | 3 | 3 | 3 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 1 |
| Withdrew: Other | 2 | 1 | 1 | 2 |
| Withdrew: Randomized but not treated | 1 | 0 | 1 | 0 |
| Milestone | Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 1: Placebo + Exemestane 25 mg | Cohort 2: Placebo + Exemestane 25 mg |
|---|---|---|---|---|
| Started | 25 | 12 | 0 | 0 |
| Treated | 24 | 11 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 25 | 12 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Withdrew: Other | 1 | 1 | 0 | 0 |
| Withdrew: Disease progression | 23 | 11 | 0 | 0 |
PFS was defined as the time in months from randomization to the first documentation of progression of disease (PD) or death on study due to any cause, whichever occurred first. PD according to response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) was defined as greater than or equal to (\>=) 20 percent (%) increase in the sum of diameters of the target lesions taking as a reference the smallest sum recorded since the start of treatment or unequivocal progression in non-target lesions or the appearance of 1 or more new lesions. The analysis of PFS was based on investigator assessment of disease progression. Participants who were not known to have had a PFS event at the analysis date were censored at last tumor assessment date prior to data cutoff or date of new treatment initiation, whichever occurred first.
| months | Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 1: Placebo + Exemestane 25 mg | Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 2: Placebo + Exemestane 25 mg |
|---|---|---|---|---|
| Progression Free Survival (PFS): Intent-to-Treat (ITT) Population By Interactive Web Recognition System (IWRS) | 11.8 (7.3 to 15.9) | 5.8 (3.5 to 10.9) | 3.6 (1.9 to 5.5) | 3.9 (2.6 to 5.4) |
PFS was defined as the time in months from randomization to the first documentation of PD or death on study due to any cause, whichever occurred first. PD according to RECIST 1.1, was defined as \>= 20% increase in the sum of diameters of the target lesions taking as a reference the smallest sum recorded since the start of treatment or unequivocal progression in non-target lesions or the appearance of 1 or more new lesions. The analysis of PFS was based on investigator assessment of disease progression. Participants who were not known to have had a PFS event at the analysis date were censored at last tumor assessment date prior to data cutoff or date of new treatment initiation, whichever occurred first.
| months | Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 1: Placebo + Exemestane 25 mg | Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 2: Placebo + Exemestane 25 mg |
|---|---|---|---|---|
| Progression Free Survival (PFS): Diagnostic Positive (DX+) Population By Interactive Web Recognition System (IWRS) | 16.5 (11.0 to NA) | 4.3 (1.9 to 10.9) | 6.0 (2.3 to 26.7) | 5.3 (1.8 to 6.7) |
CBR-24: Percentage of participants with a best response of complete response (CR), partial response (PR), or stable disease (SD) sustained for atleast 24 weeks, as determined by investigator using RECIST 1.1. CR: Disappearance of all (target and non-target) lesions and normalization of tumor marker level for non-target lesions. All lymph nodes (target and non-target) must be non-pathological in size (less than \[\<\] 10 millimeter \[mm\] short axis). PR: \>=30% decrease in sum of diameters of target lesions, using baseline sum diameters as reference. SD: Neither sufficient reduction to qualify as PR nor sufficient increase to qualify as PD, using the smallest sum diameters during study as reference. PD: \>=20% increase (an absolute increase of \>=5 mm) in sum of diameters of target lesions, using the smallest sum during the study as a reference (including baseline sum), or unequivocal progression of existing non-target lesions, or appearance of atleast 1 new target or non-target lesions.
| percentage of participants | Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 1: Placebo + Exemestane 25 mg | Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 2: Placebo + Exemestane 25 mg |
|---|---|---|---|---|
| Clinical Benefit Rate-24 (CBR-24) | 61.9 (48.8 to 73.9) | 45.3 (32.8 to 58.3) | 20.0 (10.8 to 32.3) | 31.7 (20.3 to 45.0) |
Best objective response rate: Percentage of participants with measurable disease and with a best response of CR or PR according to RECIST 1.1. CR: Disappearance of all (target and non-target) lesions and normalization of tumor marker level for non-target lesions. All lymph nodes (target and non-target) must be non-pathological in size (\<10 mm short axis). PR: Atleast 30% decrease in sum of diameters of target lesions, using baseline sum diameters as reference. Response evaluation was based on investigators' judgment.
| percentage of participants | Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 1: Placebo + Exemestane 25 mg | Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 2: Placebo + Exemestane 25 mg |
|---|---|---|---|---|
| Best Objective Response Rate | 30.8 (17.0 to 47.6) | 19.0 (8.6 to 34.1) | 9.5 (2.7 to 22.6) | 4.8 (0.6 to 16.2) |
Duration of objective response: Time from first documentation of CR or PR, to the first documentation of PD or death due to any cause, whichever occurred first as determined by investigator using RECIST 1.1. CR: Disappearance of all (target and non-target) lesions and normalization of tumor marker level for non-target lesions. All lymph nodes (target and non-target) must be non-pathological in size (\<10 mm short axis). PR: \>=30% decrease in sum of diameters of target lesions, using baseline sum diameters as reference. PD: \>=20% increase (an absolute increase of \>=5 mm) in sum of diameters of target lesions, using the smallest sum during the study as a reference (including baseline sum), or unequivocal progression of existing non-target lesions, or appearance of atleast 1 new target or non-target lesions. Participants with no PD or death (after initial CR or PR) at the analysis date were censored at last tumor assessment date prior to date of new antitumor treatment or data cutoff.
| months | Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 1: Placebo + Exemestane 25 mg | Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 2: Placebo + Exemestane 25 mg |
|---|---|---|---|---|
| Duration of Objective Response | 14.0 (5.6 to NA) | 9.1 (3.2 to 10.2) | 18.3 (3.3 to 23.1) | 4.6 (1.9 to 7.4) |
Time to response: Time from randomization to first documentation of CR or PR. CR: Disappearance of all (target and non-target) lesions and normalization of tumor marker level for non-target lesions. All lymph nodes (target and non-target) must be non-pathological in size (\<10 mm short axis). PR: \>=30% decrease in sum of diameters of target lesions, using baseline sum diameters as reference. PD: \>=20% increase (an absolute increase of \>=5 mm) in sum of diameters of target lesions, using the smallest sum during the study as a reference (including baseline sum), or unequivocal progression of existing non-target lesions, or appearance of atleast 1 new target or non-target lesions. Participants who were not known to have had a CR or PR were censored at last tumor assessment date prior to data cutoff or date of new treatment initiation, whichever occurred first.
| months | Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 1: Placebo + Exemestane 25 mg | Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 2: Placebo + Exemestane 25 mg |
|---|---|---|---|---|
| Time to Response | 12.9 (7.3 to NA) | 14.0 (7.4 to NA) | NA (3.9 to NA) | NA (NA to NA) |
Time to progression was defined as the time from the date of randomization to PD defined by the investigator using RECIST 1.1. PD: \>=20% increase (an absolute increase of \>=5 mm) in sum of diameters of target lesions, using the smallest sum during the study as a reference (including baseline sum), or unequivocal progression of existing non-target lesions, or appearance of atleast 1 new target or non-target lesions. Participants who did not experience disease progression, time to progression was right censored at the date of the last tumor assessment prior to data cutoff or date of new antitumor treatment, whichever occurred first.
| months | Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 1: Placebo + Exemestane 25 mg | Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 2: Placebo + Exemestane 25 mg |
|---|---|---|---|---|
| Time to Progression | 11.8 (7.3 to 15.9) | 7.4 (3.5 to 13.5) | 3.6 (1.9 to 5.6) | 3.9 (2.6 to 5.4) |
PFS at 6 months was defined as the percentage of participants with no event of disease progression at Month 6 landmark, estimated by Kaplan-Meier methods. PFS was defined as the time in months from randomization to the first documentation of PD or death on study due to any cause, whichever occurred first. PD: \>=20% increase (an absolute increase of \>=5 mm) in sum of diameters of target lesions, using the smallest sum during the study as a reference (including baseline sum), or unequivocal progression of existing non-target lesions, or appearance of atleast 1 new target or non-target lesions. The analysis of PFS was based on investigator assessment of disease progression.
| percentage of participants | Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 1: Placebo + Exemestane 25 mg | Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 2: Placebo + Exemestane 25 mg |
|---|---|---|---|---|
| Progression Free Survival (PFS) at 6 Months | 66.7 (53.2 to 77.0) | 50.0 (37.1 to 61.6) | 31.5 (19.7 to 43.9) | 33.3 (21.6 to 45.5) |
Concentration versus time summary was calculated by setting concentration values below limit of quantitation to zero.
| microgram per milliliter | Enzalutamide 160 mg |
|---|---|
| Day 29 | 14.2 ± 2.97 |
| Day 57 | 14.2 ± 3.21 |
| Day 113 | 13.2 ± 4.51 |
Concentration versus time summary was calculated by setting concentration values below limit of quantitation to zero.
| Picogram per milliliter | Exemestane 25 mg | Exemestane 50 mg |
|---|---|---|
| Day 29: Predose | 1010 ± 1600 | 943 ± 939 |
| Day 29: 1 hour Postdose | 17000 ± 16400 | 19200 ± 17800 |
| Day 29: 6 hour Postdose | 5590 ± 4750 | 6850 ± 9090 |
| Day 57: Predose | 1160 ± 2590 | 1100 ± 2650 |
| Day 57: 1 hour Postdose | 19900 ± 18600 | 15300 ± 14500 |
| Day 57: 6 hour Postdose | 5890 ± 4880 | 5650 ± 6200 |
| Day 113: Predose | 1160 ± 2870 | 1330 ± 3380 |
| Day 113: 1 hour Postdose | 20800 ± 18100 | 19400 ± 18500 |
| Day 113: 6 hour Postdose | 3510 ± 3850 | 5600 ± 5290 |
| Day 169: 1 hour Postdose | — | 22800 ± NA |
| Day 169: 6 hour Postdose | — | 6020 ± NA |
N-desmethyl enzalutamide was the active metabolite of enzalutamide. Concentration versus time summary was calculated by setting concentration values below limit of quantitation to zero.
| microgram per milliliter | Enzalutamide 160 mg |
|---|---|
| Day 29 | 11.6 ± 4.10 |
| Day 57 | 15.2 ± 4.76 |
| Day 113 | 15.2 ± 5.81 |
The EORTC QLQ-C30 questionnaire was a standardized instrument developed to assess the quality of life of people with cancer. Participants self-rated their self-care, activity level, pain/discomfort, and mental health during the past week by choosing 1 of 4 possible responses that recorded the level of intensity (not at all, a little, quite a bit, and very much) within each dimension, where higher score=more level of intensity. The questionnaire also asked the participants to rate their overall health or quality of life within the past week on a scale of 1 to 7, where 1 is "very poor" and 7 is "excellent". Higher global health or quality of life scores indicated better overall health or quality of life. In this outcome measure, global health/quality of life scores are presented.
| Units on a scale | Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 1: Placebo + Exemestane 25 mg | Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 2: Placebo + Exemestane 25 mg |
|---|---|---|---|---|
| Week 5 | 1.2 ± 19.14 | 1.3 ± 21.19 | -4.6 ± 16.55 | 0.3 ± 15.87 |
| Week 9 | -1.9 ± 21.21 | 1.3 ± 18.77 | -5.6 ± 19.13 | -1.3 ± 14.37 |
| Week 17 | -3.0 ± 19.46 | -1.8 ± 19.29 | -7.3 ± 24.45 | -0.8 ± 15.98 |
| Week 25 | 3.6 ± 18.17 | -3.4 ± 21.03 | 0.6 ± 18.76 | -4.8 ± 16.79 |
| Week 33 | 2.2 ± 19.60 | -0.9 ± 19.59 | -8.3 ± 17.68 | -5.0 ± 15.04 |
| Week 41 | -0.9 ± 16.11 | -1.5 ± 16.99 | -9.3 ± 17.40 | -1.4 ± 9.95 |
| Week 49 | -0.7 ± 19.53 | 0.8 ± 13.67 | -8.3 ± 12.73 | -4.2 ± 16.06 |
| Week 61 | 3.8 ± 18.32 | -5.7 ± 19.26 | -1.2 ± 20.65 | 6.3 ± 18.48 |
| Week 73 | -1.1 ± 19.64 | 0.0 ± 14.03 | -6.0 ± 15.00 | 2.1 ± 21.92 |
| Week 85 | 0.9 ± 27.78 | -5.2 ± 7.63 | -3.3 ± 18.26 | 0.0 |
| Week 97 | -8.3 ± 6.80 | -2.8 ± 6.80 | 0.0 ± 0.00 | — |
| Week 109 | -13.9 ± 17.35 | 0.0 | 12.5 ± 5.89 | — |
| Week 121 | — | -8.3 | — | — |
| Week 133 | — | 0.0 | — | — |
EORTC QLQ-BR23 was disease-specific module for breast cancer developed as supplement for EORTC QLQ-C30 that assessed quality of life of participants with breast cancer.Participants self-rated on frequent symptoms or problems reported by participants with breast cancer,e.g., pain/discomfort, body satisfaction, and self-esteem during past week by choosing 1 of 4 possible responses that recorded level of intensity (not at all, a little, quite a bit, and very much) within each dimension.Raw scores were then transformed to 0-100 scale for analysis and interpretation, where higher scores=more level of intensity, as per EORTC guidelines.Participants also self-rated on sexual health/interest during last 4 weeks using same scale. In this outcome measure body image functioning, sexual functioning, systemic therapy side effects, upset by hair loss parameters were assessed by EORTC QLQ-BR23 questionnaire,total score for each parameter ranged from 0-100,where higher scores=more level of intensity.
| units on a scale | Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 1: Placebo + Exemestane 25 mg | Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 2: Placebo + Exemestane 25 mg |
|---|---|---|---|---|
| Body Image Functioning: Week 5 | 1.8 ± 16.01 | 1.9 ± 19.10 | -6.1 ± 13.92 | 2.2 ± 15.74 |
| Body Image Functioning: Week 9 | -3.5 ± 12.91 | -0.2 ± 17.91 | -3.7 ± 12.51 | 2.1 ± 15.58 |
| Body Image Functioning: Week 17 | -2.9 ± 20.16 | -3.5 ± 19.24 | -9.0 ± 19.34 | 1.3 ± 13.98 |
| Body Image Functioning: Week 25 | 2.8 ± 16.55 | -7.4 ± 24.24 | -9.4 ± 16.33 | -0.8 ± 7.86 |
| Body Image Functioning: Week 33 | -2.9 ± 22.08 | -5.7 ± 17.55 | -1.9 ± 9.11 | -1.8 ± 8.12 |
| Body Image Functioning: Week 41 | -2.5 ± 18.76 | -1.3 ± 13.36 | 0.0 ± 4.17 | 4.2 ± 14.43 |
| Body Image Functioning: Week 49 | -2.4 ± 19.79 | -5.2 ± 17.57 | -1.2 ± 3.15 | 1.0 ± 8.26 |
| Body Image Functioning: Week 61 | 3.3 ± 19.94 | -5.7 ± 15.23 | -4.8 ± 6.56 | 0.0 ± 13.61 |
| Body Image Functioning: Week 73 | -3.2 ± 29.70 | -3.2 ± 12.05 | 1.2 ± 5.75 | 4.2 ± 10.76 |
| Body Image Functioning: Week 85 | 8.3 ± 28.05 | -13.5 ± 24.78 | 1.7 ± 3.73 | -16.7 |
| Body Image Functioning: Week 97 | -5.6 ± 17.35 | -1.4 ± 3.40 | -4.2 ± 5.89 | — |
| Body Image Functioning: Week 109 | 0.0 ± 35.36 | 0.0 | -8.3 ± 11.79 | — |
| Body Image Functioning: Week 121 | — | 0.0 | — | — |
| Body Image Functioning: Week 133 | — | 0.0 | — | — |
| Sexual Functioning: Week 5 | 1.9 ± 12.08 | -0.3 ± 13.40 | 0.3 ± 17.00 | 1.9 ± 10.16 |
| Sexual Functioning: Week 9 | 2.3 ± 16.15 | -1.4 ± 16.78 | 1.3 ± 15.68 | 2.8 ± 11.73 |
| Sexual Functioning: Week 17 | 3.3 ± 15.65 | 0.0 ± 20.21 | 7.2 ± 23.48 | 0.6 ± 12.18 |
| Sexual Functioning: Week 25 | 1.4 ± 17.33 | 0.5 ± 19.16 | 0.0 ± 25.20 | 1.8 ± 10.96 |
| Sexual Functioning: Week 33 | 4.0 ± 20.43 | 3.0 ± 12.05 | 7.4 ± 22.22 | 4.2 ± 12.56 |
| Sexual Functioning: Week 41 | 2.4 ± 23.00 | 0.8 ± 15.34 | 9.3 ± 22.22 | 1.7 ± 9.46 |
| Sexual Functioning: Week 49 | 7.1 ± 21.69 | 5.8 ± 11.18 | 9.5 ± 26.97 | 0.0 ± 0.0 |
| Sexual Functioning: Week 61 | 7.4 ± 21.56 | 1.9 ± 20.52 | 7.1 ± 25.20 | 0.0 ± 13.61 |
| Sexual Functioning: Week 73 | 8.3 ± 16.98 | 2.8 ± 13.91 | 9.5 ± 31.71 | 4.2 ± 8.33 |
| Sexual Functioning: Week 85 | 7.4 ± 22.22 | 4.8 ± 15.85 | -6.7 ± 27.89 | 0.0 |
| Sexual Functioning: Week 97 | -5.6 ± 25.46 | 6.7 ± 9.13 | 16.7 ± 23.57 | — |
| Sexual Functioning: Week 109 | 0.0 ± 16.67 | 0.0 | 33.3 ± 0.00 | — |
| Sexual Functioning: Week 121 | — | 0.0 | — | — |
| Sexual Functioning: Week 133 | — | 0.0 | — | — |
| Systemic Therapy Side Effects Symptoms: Week 5 | 4.5 ± 10.59 | 3.7 ± 10.06 | 7.1 ± 11.49 | 3.3 ± 10.82 |
| Systemic Therapy Side Effects Symptoms: Week 9 | 7.5 ± 15.24 | 2.7 ± 10.24 | 6.5 ± 11.32 | 3.9 ± 10.77 |
| Systemic Therapy Side Effects Symptoms: Week 17 | 7.5 ± 10.81 | 2.0 ± 8.79 | 7.6 ± 16.61 | 6.0 ± 12.51 |
| Systemic Therapy Side Effects Symptoms: Week 25 | 8.3 ± 13.90 | 2.3 ± 7.35 | 5.6 ± 10.86 | 5.7 ± 16.05 |
| Systemic Therapy Side Effects Symptoms: Week 33 | 6.5 ± 13.54 | -0.2 ± 9.74 | 8.5 ± 7.05 | 5.3 ± 13.10 |
| Systemic Therapy Side Effects Symptoms: Week 41 | 8.4 ± 10.03 | 1.3 ± 9.20 | 10.6 ± 4.63 | 2.0 ± 10.04 |
| Systemic Therapy Side Effects Symptoms: Week 49 | 7.8 ± 10.18 | 2.5 ± 11.03 | 9.7 ± 12.78 | 7.7 ± 9.84 |
| Systemic Therapy Side Effects Symptoms: Week 61 | 7.6 ± 11.07 | 2.5 ± 10.45 | 14.7 ± 10.11 | 4.8 ± 6.73 |
| Systemic Therapy Side Effects Symptoms: Week 73 | 4.9 ± 11.90 | 4.4 ± 6.29 | 11.6 ± 10.95 | -1.2 ± 5.99 |
| Systemic Therapy Side Effects Symptoms: Week 85 | 10.7 ± 12.58 | 2.4 ± 8.82 | 9.5 ± 6.73 | 4.8 |
| Systemic Therapy Side Effects Symptoms: Week 97 | 8.2 ± 13.52 | 3.2 ± 10.29 | 7.1 ± 10.10 | — |
| Systemic Therapy Side Effects Symptoms: Week 109 | 14.1 ± 9.71 | 4.8 | 9.5 ± 6.73 | — |
| Systemic Therapy Side Effects Symptoms: Week 121 | — | 9.5 | — | — |
| Systemic Therapy Side Effects Symptoms: Week 133 | — | 4.8 | — | — |
| Upset by Hair Loss: Week 5 | -5.6 ± 19.25 | 18.2 ± 31.14 | 0.0 ± 28.01 | 0.0 ± 24.62 |
| Upset by Hair Loss: Week 9 | 0.0 ± 36.51 | 23.3 ± 31.62 | -6.7 ± 18.69 | 3.3 ± 24.60 |
| Upset by Hair Loss: Week 17 | 0.0 ± 21.08 | 9.5 ± 16.27 | 3.7 ± 20.03 | 0.0 ± 36.51 |
| Upset by Hair Loss: Week 25 | -6.7 ± 14.91 | 28.6 ± 35.63 | 26.7 ± 27.89 | -8.3 ± 16.67 |
| Upset by Hair Loss: Week 33 | 0.0 ± 23.57 | -6.7 ± 14.91 | 20.0 ± 29.81 | 0.0 ± 0.00 |
| Upset by Hair Loss: Week 41 | -16.7 ± 33.33 | 0.00 ± 0.00 | 13.3 ± 18.26 | 16.7 ± 23.57 |
| Upset by Hair Loss: Week 49 | 6.7 ± 36.51 | 0.0 ± 0.0 | 11.1 ± 19.25 | 0.0 ± 0.0 |
| Upset by Hair Loss: Week 61 | 11.1 ± 19.25 | 16.7 ± 23.57 | 25.0 ± 31.91 | — |
| Upset by Hair Loss: Week 73 | 0.0 ± 0.0 | 0.0 | 40.0 ± 43.46 | — |
| Upset by Hair Loss: Week 85 | 33.3 | — | 0.0 ± 0.0 | — |
| Upset by Hair Loss: Week 97 | — | — | 0.0 | — |
| Upset by Hair Loss: Week 109 | — | — | 0.0 ± 0.0 | — |
No measurements were reported for this outcome.
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious AEs.
| Participants | Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 1: Placebo + Exemestane 25 mg | Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 2: Placebo + Exemestane 25 mg |
|---|---|---|---|---|
| AEs | 59 | 58 | 58 | 53 |
| SAEs | 14 | 13 | 10 | 8 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severity of the AEs was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Only the participants with treatment-emergent AEs of grade 3 (severe) or higher grade were reported in this outcome measure.
| Participants | Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 1: Placebo + Exemestane 25 mg | Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 2: Placebo + Exemestane 25 mg |
|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events of Grade 3 or Higher Severity | 21 | 16 | 22 | 12 |
Criteria for clinically significant vital sign abnormalities: Systolic blood pressure (SBP): absolute SBP \<90 millimeters of mercury (mmHg) and decrease from baseline (DFB) \>30 mmHg, absolute SBP\>180 mmHg and increase from baseline (IFB) \>40 mmHg, final visit or 2 consecutive visits SBP \>=20 mmHg change from baseline (CFB), most extreme post-baseline SBP \>=140 mmHg, most extreme post-baseline SBP \>=180 mmHg, most extreme SBP \>=140 mmHg and \>=20 mmHg CFB, most extreme SBP \>=180 mmHg and \>=20 mmHg CFB; diastolic blood pressure (DBP): absolute DBP \> 105 mmHg and IFB \>30 mmHg, absolute DBP \<50 mmHg and DFB \>20 mmHg, final visit or 2 consecutive visits DBP \>=15 mmHg CFB, most extreme post-baseline DBP \>=90 mmHg, most extreme post-baseline DBP \>=105 mmHg, most extreme DBP \>=90 mmHg and \>=15 mmHg CFB, most extreme DBP \>=105 mmHg and \>=15 mmHg CFB; heart rate \<50 beats per minute (BPM) and DFB \>20 BPM or heart rate \>120 BPM and IFB \>30 BPM.
| Participants | Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 1: Placebo + Exemestane 25 mg | Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 2: Placebo + Exemestane 25 mg |
|---|---|---|---|---|
| Blood pressure | 38 | 39 | 43 | 25 |
| Heart rate | 0 | 2 | 0 | 0 |
Laboratory tests included hematology (hematocrit, hemoglobin, platelet count, red blood cell count, total neutrophils \[absolute\] and white blood cell count with differential) and serum chemistry (albumin, alkaline phosphatase, alanine aminotransferase \[ALT\], aspartate transaminase \[AST\], blood urea nitrogen and creatinine, calcium, sodium, potassium, chloride, glucose (non-fasting), lactate dehydrogenase, magnesium, phosphorus/phosphate, total bilirubin, total bicarbonate, total protein and uric acid). Clinically significant abnormality evaluation was based on clinical investigator's judgment.
| Participants | Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 1: Placebo + Exemestane 25 mg | Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 2: Placebo + Exemestane 25 mg |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Laboratory Abnormalities | 0 | 0 | 0 | 0 |
PFS was defined as the time in months from randomization to the first documentation of PD or death on study due to any cause, whichever occurred first. PD according to RECIST 1.1 was defined \>=20 % increase in the sum of diameters of the target lesions taking as a reference the smallest sum recorded since the start of treatment or unequivocal progression in non-target lesions or the appearance of 1 or more new lesions. The analysis of PFS was based on investigator assessment of disease progression. Participants who were not known to have had a PFS event at the analysis date were censored at last tumor assessment date prior to data cutoff or date of new treatment initiation, whichever occurred first. Cht 1: Enz + Exe = Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg; Cht 2: Enz + Exe= Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg
| Months | Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 1: Placebo + Exemestane 25 mg | Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 2: Placebo + Exemestane 25 mg |
|---|---|---|---|---|
| Progression Free Survival (PFS): By Electronic Data Capture (EDC) | 11.8 (7.3 to 14.6) | 5.8 (3.5 to 10.9) | 3.6 (1.9 to 5.6) | 3.9 (2.6 to 5.4) |
PFS was defined as the time in months from randomization to the first documentation of PD or death on study due to any cause, whichever occurred first. PD according to RECIST 1.1, was defined as \>= 20% increase in the sum of diameters of the target lesions taking as a reference the smallest sum recorded since the start of treatment or unequivocal progression in non-target lesions or the appearance of 1 or more new lesions. The analysis of PFS was based on investigator assessment of disease progression. Participants who were not known to have had a PFS event at the analysis date were censored at last tumor assessment date prior to data cutoff or date of new treatment initiation, whichever occurred first.
| Months | Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 1: Placebo + Exemestane 25 mg | Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 2: Placebo + Exemestane 25 mg |
|---|---|---|---|---|
| Progression Free Survival (PFS): Diagnostic Positive (DX+) Population By Electronic Data Capture (EDC) | 16.9 (11.0 to NA) | 4.3 (1.9 to 10.9) | 6.0 (3.5 to 16.6) | 5.3 (1.8 to 6.7) |
Collected over Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (up to 10.13 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | 2/62 (3.2%) | 14/62 (22.6%) | 59/62 (95.2%) |
| Cohort 1: Placebo + Exemestane 25 mg | 8/63 (12.7%) | 13/63 (20.6%) | 57/63 (90.5%) |
| Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | 3/60 (5%) | 10/60 (16.7%) | 57/60 (95%) |
| Cohort 2: Placebo + Exemestane 25 mg | 2/60 (3.3%) | 8/60 (13.3%) | 52/60 (86.7%) |
| Event | Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 1: Placebo + Exemestane 25 mg | Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 2: Placebo + Exemestane 25 mg |
|---|---|---|---|---|
| HYPERCALCAEMIAMetabolism and nutrition disorders | 2/62 | 0/63 | 2/60 | 1/60 |
| ANAEMIABlood and lymphatic system disorders | 0/62 | 0/63 | 1/60 | 0/60 |
| CARDIAC FAILURE CONGESTIVECardiac disorders | 0/62 | 0/63 | 0/60 | 1/60 |
| GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders | 0/62 | 0/63 | 1/60 | 0/60 |
| INTESTINAL OBSTRUCTIONGastrointestinal disorders | 0/62 | 0/63 | 1/60 | 0/60 |
| DISEASE PROGRESSIONGeneral disorders | 0/62 | 1/63 | 1/60 | 0/60 |
| FACIAL PAINGeneral disorders | 0/62 | 0/63 | 1/60 | 0/60 |
| FATIGUEGeneral disorders | 0/62 | 0/63 | 1/60 | 0/60 |
| GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders | 0/62 | 0/63 | 1/60 | 0/60 |
| CHOLECYSTITISHepatobiliary disorders | 0/62 | 0/63 | 1/60 | 0/60 |
| Event | Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 1: Placebo + Exemestane 25 mg | Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 2: Placebo + Exemestane 25 mg |
|---|---|---|---|---|
| NAUSEAGastrointestinal disorders | 24/62 | 10/63 | 18/60 | 11/60 |
| FATIGUEGeneral disorders | 24/62 | 23/63 | 21/60 | 13/60 |
| HOT FLUSHVascular disorders | 19/62 | 14/63 | 14/60 | 9/60 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 15/62 | 11/63 | 10/60 | 7/60 |
| DIARRHOEAGastrointestinal disorders | 14/62 | 10/63 | 7/60 | 11/60 |
| BACK PAINMusculoskeletal and connective tissue disorders | 11/62 | 6/63 | 4/60 | 11/60 |
| CONSTIPATIONGastrointestinal disorders | 11/62 | 7/63 | 8/60 | 8/60 |
| VOMITINGGastrointestinal disorders | 11/62 | 7/63 | 6/60 | 3/60 |
| HEADACHENervous system disorders | 9/62 | 6/63 | 9/60 | 10/60 |
| COUGHRespiratory, thoracic and mediastinal disorders | 10/62 | 8/63 | 2/60 | 4/60 |
Intent-to-treat (ITT) population included all the participants randomly assigned to double-blind study treatment.
| Age, Categorical(Participants) | Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 1: Placebo + Exemestane 25 mg | Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 2: Placebo + Exemestane 25 mg | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 42 | 32 | 37 | 40 | 151 |
| >=65 years | 21 | 32 | 23 | 20 | 96 |
| Sex: Female, Male(Participants) | Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 1: Placebo + Exemestane 25 mg | Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 2: Placebo + Exemestane 25 mg | Total |
|---|---|---|---|---|---|
| Female | 63 | 64 | 60 | 60 | 247 |
| Male | 0 | 0 | 0 | 0 | 0 |
Showing the first 100 of 135 sites across 7 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
No publications or documents are linked to this record.
Ran from Dec 2013 to primary completion in Sep 2016, 33 months.
Results were first posted in Feb 2018, 1 year 4 months after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 33 months is close to that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enzalutamide